Compare MFIC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFIC | INBX |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 999.7M |
| IPO Year | N/A | 2024 |
| Metric | MFIC | INBX |
|---|---|---|
| Price | $11.00 | $117.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $11.25 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 660.4K | 582.2K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | ★ 10.84% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.50 | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $9.48 | $12.80 |
| 52 Week High | $13.51 | $155.29 |
| Indicator | MFIC | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 38.46 | 53.89 |
| Support Level | $10.92 | $69.30 |
| Resistance Level | $11.81 | $155.29 |
| Average True Range (ATR) | 0.30 | 12.57 |
| MACD | -0.12 | -2.94 |
| Stochastic Oscillator | 1.18 | 34.41 |
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.